Skip to content

Transcranial direct current stimulation improves prospective memory in schizophrenia and its mechanism

Transcranial direct current stimulation improves prospective memory in schizophrenia and its mechanism

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070832
Enrollment
Unknown
Registered
2023-04-24
Start date
2022-03-20
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Sponsors

Beijing Anding Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Patients meeting DSM-5 criteria for schizophrenia spectrum disorder 2.Patients aged 18-50 years, with right handedness 3.Patients with IQ > 70,years of education =7 4.Patients with PANSS score at most 5 in the following items: P1 delusion, P3 hallucination, P5 exaggeration, P6 suspicion / victimization, G9 abnormal thinking content; PANSS score at most 4 in the following item: P2 concept disorder 5.Patients who are clinically stable, maintained on current antipsychotic and concomitant medications for at least 6 weeks, with no change in antipsychotic dose for at least 2 weeks. Patients must take the same type and dose of antipsychotic medications during the study period. 6.The Cambridge Prospective Memory Test score was below average

Exclusion criteria

Exclusion criteria: 1.Patients with cochlear implantation devices or other metal implanted in the body; 2.Patients with color blindness or color weakness; 3.Patients who are pregnant or lactating women; 4.Patients with severe nervous system diseases (history of craniocerebral trauma or infection, brain tumor, cerebrovascular disease, epilepsy, etc.) or other severe physical diseases; 5.Patients with unstable mental state (suicidal intention or impulsive behavior); 6.Patients with a history of alcohol and drug abuse or dependence within 6 months; 7.Patients taking sedative-hypnotic drugs at a dose greater than lorazepam 1 mg / day or equivalent; 8.Patients taking anticholinergic drugs at a dose greater than trihexyphenidyl 10 mg / day or equivalent; 9.Patients taking stimulants (e.g., methylphenidate, dextroamphetamine, modafinil), or receiving electroconvulsive therapy or electromagnetic stimulation or cognitive training within 6 months; 10.Patients receiving repeat assessments using MCCB and/or other cognitive test kits within 12 weeks (i.e., single assessment is not excluded); 11.Patients who are unable or unwilling to cooperate with effective evaluation and treatment.

Design outcomes

Primary

MeasureTime frame
the accuracy of prospective memory trials in eye-tracking paradigm;

Secondary

MeasureTime frame
the accuracy of prospective memory trials in eye-tracking paradigm;MATRICS Consensus Cognitive Battery scores;stroop color word test scores;PANSS scores;Adverse effects of tDCS;Cambridge Prospective Memory Test scores;resting-state functional MRI;fixation counts of distractor words in eye-tracking paradigm;fixation time of distractor words in eye-tracking paradigm;

Countries

China

Contacts

Public ContactFuchun Zhou

Beijing Anding Hospital Affiliated to Capital Medical University

psychosomatist@163.com+86 10 58303195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026